Skip to main content

Thermo Fisher Scientific Inc. (TN8.DE)

Frankfurt Stock Exchange (XETRA) Healthcare Medical - Diagnostics & ResearchView data quality →
52.1Fair

ValueMarkers Composite Index

Top 38%#27,736 of 44,714
Overvalued

44% above intrinsic value ($297)

UndervaluedFair ValueOvervalued
Piotroski
4/9
Neutral
Beneish
-2.54
Low Risk
Altman
3.22
Safe
DCF Value
$297
Overvalued
ROIC
7.5%
Low
P/E
28.8
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Thermo Fisher Scientific Inc. (TN8.DE) — VMCI valuation read

Headline read on TN8.DE: VMCI of 52/100 versus a Healthcare sector median of 50. The 2-point above-median position is what makes Thermo Fisher Scientific Inc. a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on TN8.DE: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on TN8.DE: value (TN8.DE trades at 25.0x earnings, 39% above the Healthcare median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -1.8x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

TN8.DE rose 2.1% over the trailing 7 days, with a -11.0% read on a 30-day basis.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

CEO: Marc N. Casper125,000 employeesUSwww.thermofisher.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in TN8.DE’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.